Skip to main content
Equibles
SUPN logo

SUPN · Supernus Pharmaceuticals, Inc. · Metrics

Track SUPN — free

Use SUPN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SUPN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$41.21 -0.02 (-0.05%) At close · Oct 21
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.40B
Shares
58.13M
Volume · Oct 21 1.01M Avg daily vol (3M) 816.71K

SUPN metrics

95 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$41.21
Market cap
$2.40B

Price action

20 metrics
Price change (1W)
-1.9%
Price change (30D)
-3.6%
Price change (3M)
-13.9%
Price change (6M)
-16.1%
Price change (YTD)
-17.0%
Price change (1Y)
-20.1%
Trailing year
Price change (5Y)
+37.9%
52-week high
$57.00
52-week low
$37.88
Change from 52-week high
-27.7%
Change from 52-week low
+8.8%
Annualized volatility
37.0%
Annualized volatility (3M)
37.2%
Beta
0.6
RSI (14D)
46.3
Price vs SMA 50
-5.3%
Price vs SMA 200
-13.5%
Avg volume (3M)
808,159
Relative volume
1.5
Average dollar volume
$35.56M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
58.13M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.8×
reciprocal yield 35.9%
P / book
2.2
reciprocal yield 44.5%
FCF yield
0.8%
TTM · current market cap
Buyback yield
—
P / FCF
123.3
reciprocal yield 0.8%
P / operating cash flow
116.3
reciprocal yield 0.9%
Earnings yield
-4.7%

Historical valuation

8 metrics
P / E historical average (3Y)
35.5×
reciprocal yield 2.8%
P / E historical average (5Y)
26.8×
reciprocal yield 3.7%
EV / revenue historical average (3Y)
2.8×
reciprocal yield 35.2%
EV / revenue historical average (5Y)
2.8×
reciprocal yield 35.2%
EV / EBIT historical average (3Y)
60.8×
reciprocal yield 1.6%
EV / EBIT historical average (5Y)
60.8×
reciprocal yield 1.6%
EV / EBITDA historical average (3Y)
54.6×
reciprocal yield 1.8%
EV / EBITDA historical average (5Y)
54.6×
reciprocal yield 1.8%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-29
Last earnings
2026-08-03

Profitability

9 metrics
Gross margin
88.1%
Operating margin
-15.7%
Trailing 12 months
Net margin
-13.2%
Gross profit (TTM)
$731.41M
Operating profit (TTM)
−$130.46M
Net income (TTM)
−$109.89M
Trailing 12 months
Diluted EPS (TTM)
$-1.92
FCF margin
2.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$14.50
Gross profit per diluted share (TTM)
$12.77
Operating profit per diluted share (TTM)
$-2.28
EBITDA per diluted share (TTM)
$-0.57
Net income per diluted share (TTM)
$-1.92
Operating cash flow per diluted share (TTM)
$0.33
Free cash flow per diluted share (TTM)
$0.31
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$2.20
Stock compensation per diluted share (TTM)
$0.60
Book value per share
$18.48

Growth

11 metrics
Revenue growth YoY
+32.4%
Year over year
Net income growth YoY
-359.4%
Revenue (TTM)
$830.44M
Trailing 12 months
EPS growth YoY
-352.5%
Shares change YoY
+2.5%
Year over year · more shares
Revenue CAGR (3Y)
+2.5%
Revenue CAGR (5Y)
+6.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
-26.6%
FCF CAGR (5Y)
-19.4%

Quality

14 metrics
Return on equity
-10.7%
Return on assets
-7.7%
Debt / equity
—
Current ratio
2.1
EBITDA (TTM)
−$33.25M
Free cash flow (TTM)
$18.79M
Quick ratio
1.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$179.95M
Total assets
$1.43B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$19.91M
Capital expenditures (TTM)
$1.12M
R&D (TTM)
$126.09M
SG&A (TTM)
$560.88M
Stock compensation (TTM)
$34.60M
R&D / revenue
15.2%
Stock compensation / revenue
4.2%

Ownership (13F)

9 metrics
13F filers
336
13F filer change QoQ
+6
Institutional ownership
103.9%
Conviction holders (share of 13F filers)
0.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+2.9%
Holder tenure
15.3
Price vs estimated holder cost
+4.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
28.5%

Short interest

3 metrics
Short interest
8.6%
Latest settlement · 7.4 days to cover
Days to cover
7.4d
Short-squeeze score
82 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1356576 CUSIP 868459108 13F (30d) 37 filings 36 filers Visit website Investor relations